Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Samantha Robare

Dermatology Cypress, TX Medical Doctor

NPI 1306161211 CMS profile 13923

10547 Fry Rd, Cypress, TX 77433

Open in the dashboard

General payments

$76,270

1,239 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Samantha Robare of Cypress, TX is reported in the CMS Open Payments database as having received $76,270 across 1,239 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,628 208
2024 General $3,070 160
2023 General $3,007 172
2022 General $2,829 148
2021 General $7,140 143
2020 General $23,417 138
2019 General $32,178 270

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samantha Robare
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Samantha Robare were reported at $4,628. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Samantha Robare Dermatology median Middle half National median
2019 $32,178 $454 $129–$1,240 $163
2020 $23,417 $235 $81–$756 $114
2021 $7,140 $377 $108–$1,108 $132
2022 $2,829 $514 $143–$1,391 $149
2023 $3,007 $607 $159–$1,674 $160
2024 $3,070 $751 $204–$1,903 $164
2025 $4,628 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Galderma Laboratories, L.P. $23,574 103 payments
  2. Janssen Scientific Affairs, LLC $21,324 23 payments
  3. Novartis Pharmaceuticals Corporation $13,859 174 payments
  4. AbbVie, Inc. $3,182 163 payments
  5. Sun Pharmaceutical Industries Inc. $1,786 86 payments
  6. Janssen Biotech, Inc. $1,677 91 payments
  7. Pfizer Inc. $1,449 111 payments
  8. Lilly USA, LLC $1,321 72 payments
  9. Regeneron Healthcare Solutions, Inc. $1,173 43 payments
  10. Lumenis BE inc $974 1 payment
  11. Other $5,951 372 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $50,523 33 payments
  2. Food and Beverage $22,645 1,190 payments
  3. Travel and Lodging $2,759 9 payments
  4. Education $343 7 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $22,878 104 payments
  2. EPIDUO FORTE $17,486 25 payments
  3. COSENTYX Dermatology $9,062 23 payments
  4. AKLIEF $8,016 23 payments
  5. COSENTYX Immunology $3,589 80 payments
  6. SKYRIZI $1,231 68 payments
  7. TALTZ $1,164 62 payments
  8. ILUMYA $1,130 58 payments
  9. COSENTYX Dermatology $1,095 65 payments
  10. DUPIXENT $1,035 36 payments
  11. Other $15,385 878 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

395

Median for Dermatology: 534

Drug cost

$177,880

Median for Dermatology: $67,151

Branded share of claims

17.2%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Otezla Apremilast Brand 22 $96,664
Rinvoq Upadacitinib Brand 11 $75,083
Doxycycline Hyclate Generic 53 $1,069
Dutasteride Generic 17 $1,039
Betamethasone Diprop Augmented Betamethasone/Propylene Glyc Brand 35 $897
Triamcinolone Acetonide Generic 95 $792
Imiquimod Generic 23 $754
Clobetasol Propionate Generic 23 $574
Ketoconazole Generic 32 $449
Finasteride Generic 19 $248

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$152,837

Of which drugs: $17

Medicare patients

382

Average age 73

Services billed

2,653

205 women, 177 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 44%
Ischemic heart disease 32%
Diabetes 23%
Osteoporosis 21%
Atrial fibrillation 16%
Chronic kidney disease 15%
COPD 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 14 22 $17

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
$332 11 —
ILUMYA
$287 — —
TREMFYA
$277 — —
DUPIXENT
$268 — —
COSENTYX
$267 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

1,239 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record